Mark Kagan

975 total citations
19 papers, 778 citations indexed

About

Mark Kagan is a scholar working on Molecular Biology, Oncology and Spectroscopy. According to data from OpenAlex, Mark Kagan has authored 19 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Spectroscopy. Recurrent topics in Mark Kagan's work include Analytical Chemistry and Chromatography (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Metabolomics and Mass Spectrometry Studies (2 papers). Mark Kagan is often cited by papers focused on Analytical Chemistry and Chromatography (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Metabolomics and Mass Spectrometry Studies (2 papers). Mark Kagan collaborates with scholars based in United States, Switzerland and United Kingdom. Mark Kagan's co-authors include Klaus D. Brunnemann, Jonathan E. Cox, Dietrich Hoffmann, Stephen S. Hecht, Steven G. Carmella, Assieh A. Melikian, Heyi Li, James H. Resau, Shobha A. Akerkar and Gary D. Stoner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mark Kagan

19 papers receiving 737 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Kagan United States 12 309 286 218 100 81 19 778
Miriam Verwei Netherlands 19 140 0.5× 262 0.9× 224 1.0× 87 0.9× 198 2.4× 24 1.3k
Parvaneh Espandiari United States 19 171 0.6× 279 1.0× 302 1.4× 63 0.6× 55 0.7× 29 865
U. Andrae Germany 18 402 1.3× 443 1.5× 188 0.9× 42 0.4× 78 1.0× 43 975
Jaroslav Mráz Czechia 17 250 0.8× 206 0.7× 165 0.8× 47 0.5× 64 0.8× 62 751
Daniela Keller Germany 13 90 0.3× 235 0.8× 144 0.7× 155 1.6× 164 2.0× 17 791
D Ratnasinghe United States 19 394 1.3× 763 2.7× 129 0.6× 39 0.4× 201 2.5× 22 1.4k
G.D. Sweeney Canada 21 248 0.8× 484 1.7× 308 1.4× 59 0.6× 106 1.3× 49 1.4k
Kimberley A. O’Hara Canada 16 113 0.4× 378 1.3× 215 1.0× 52 0.5× 91 1.1× 24 845
Melissa Goggin United States 17 329 1.1× 443 1.5× 130 0.6× 23 0.2× 111 1.4× 27 810
David R. Plowchalk United States 20 149 0.5× 270 0.9× 195 0.9× 52 0.5× 264 3.3× 27 1.4k

Countries citing papers authored by Mark Kagan

Since Specialization
Citations

This map shows the geographic impact of Mark Kagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kagan more than expected).

Fields of papers citing papers by Mark Kagan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Kagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kagan. The network helps show where Mark Kagan may publish in the future.

Co-authorship network of co-authors of Mark Kagan

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Kagan. A scholar is included among the top collaborators of Mark Kagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Kagan. Mark Kagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Smith, William B., Timothy M. Clough, Mark Kagan, et al.. (2024). A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons. The Journal of Clinical Endocrinology & Metabolism. 110(3). 771–786. 9 indexed citations
2.
Nelson, Robert, et al.. (2024). Immunogenicity assessment strategy for a chemically modified therapeutic protein in clinical development. Frontiers in Immunology. 15. 1438251–1438251. 1 indexed citations
3.
Miao, Zhuang, Lai Wang, Helen Gu, et al.. (2021). Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism. Drug Metabolism and Disposition. 49(7). 548–562. 3 indexed citations
4.
Schadt, Simone, Bojan Bister, Swapan K. Chowdhury, et al.. (2018). A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the “Metabolites in Safety Testing” Regulatory Guidance. Drug Metabolism and Disposition. 46(6). 865–878. 78 indexed citations
5.
Davis, John A., Mark Kagan, Jessica Read, Markus Walles, & Panos Hatsis. (2017). Immunoprecipitation Middle-Up LC–MS for In Vivo Drug-To-Antibody Ratio Determination for Antibody–Drug Conjugates. Bioanalysis. 9(20). 1535–1549. 13 indexed citations
6.
Manley, Paul W., et al.. (2013). Clinical and Preclinical Characterisation Of The Metabolites Of The BCR-ABL Tyrosine Kinase Inhibitor Nilotinib. Blood. 122(21). 4011–4011. 1 indexed citations
7.
8.
Kagan, Mark, et al.. (2012). Metabolism and Pharmacokinetics of Indacaterol in Humans. Drug Metabolism and Disposition. 40(9). 1712–1722. 19 indexed citations
9.
Clive, Sally, et al.. (2009). Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat. Journal of Clinical Oncology. 27(15_suppl). 2549–2549. 8 indexed citations
10.
Kagan, Mark, Volker Fischer, Paula Savage, et al.. (2005). Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.. Blood. 106(11). 4887–4887. 21 indexed citations
11.
Qu, Qingshan, Assieh A. Melikian, Guilan Li, et al.. (2000). Validation of biomarkers in humans exposed to benzene: Urine metabolites. American Journal of Industrial Medicine. 37(5). 522–531. 99 indexed citations
12.
Melikian, Assieh A., Ray O’Connor, Agasanur K. Prahalad, et al.. (1999). Determination of the urinary benzene metabolites S-phenylmercapturic acid and trans,trans-muconic acid by liquid chromatography-tandem mass spectrometry. Carcinogenesis. 20(4). 719–726. 87 indexed citations
13.
Hecht, Stephen S., et al.. (1991). Quantification of 4-hydroxy-1-(3-pyridyl)-1-butanone released from human haemoglobin as a dosimeter for exposure to tobacco-specific nitrosamines.. PubMed. 113–8. 2 indexed citations
14.
Foiles, Peter G., Shobha A. Akerkar, Steven G. Carmella, et al.. (1991). Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chemical Research in Toxicology. 4(3). 364–368. 100 indexed citations
15.
Djordjevic, Mirjana V., Dietrich Hoffmann, Klaus D. Brunnemann, et al.. (1991). Assessment of major carcinogens and alkaloids in the tobacco and mainstream smoke of ussr cigarettes. International Journal of Cancer. 47(3). 348–351. 24 indexed citations
16.
Brunnemann, Klaus D., Mark Kagan, Jonathan E. Cox, & Dietrich Hoffmann. (1990). Analysis of 1,3-butadiene and other selected gas-phase components in cigarette mainstream and sidestream smoke by gas chromatography-mass selective detection. Carcinogenesis. 11(10). 1863–1868. 130 indexed citations
17.
Carmella, Steven G., et al.. (1990). Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff dippers, smokers, and nonsmokers.. PubMed. 50(17). 5438–45. 81 indexed citations
18.
Brunnemann, Klaus D., Mark Kagan, Jonathan E. Cox, & D. Hoffmann. (1989). Determination of benzene, toluene and 1,3-butadiene in cigarette smoke by GC-MSD. Experimental Pathology. 37(1-4). 108–113. 41 indexed citations
19.
LaVoie, Edmond J., et al.. (1989). Analyses of steam distillates and aqueous extracts of smokeless tobacco. Journal of Agricultural and Food Chemistry. 37(1). 154–157. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miriam Verwei Breakdown of academic impact, for papers by Parvaneh Espandiari Breakdown of academic impact, for papers by U. Andrae Breakdown of academic impact, for papers by Jaroslav Mráz Breakdown of academic impact, for papers by Daniela Keller Breakdown of academic impact, for papers by D Ratnasinghe Breakdown of academic impact, for papers by G.D. Sweeney Breakdown of academic impact, for papers by Kimberley A. O’Hara Breakdown of academic impact, for papers by Melissa Goggin Breakdown of academic impact, for papers by David R. Plowchalk
Rankless by CCL
2026